Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
South Korea-based pharmaceutical company Celltrion Inc. received approval for its new drug, Remsima SC, from the US Food and Drug Administration (FDA). The drug offers a promising treatment option for individuals suffering from autoimmune diseases.
It contains the active ingredient infliximab, also known as Zymfentra in the American market, the Yonhap News Agency noted.
New Drug Approval and Patents
Remsima SC marks Celltrion's first FDA-approved drug. The company has filed a patent application to safeguard its proprietary rights, focusing on the drug's formulation and mode of administration, to maintain exclusivity until 2040.
Zymfentra, the subcutaneous injection (SC) variant of the antibody biosimilar Remsima, expands Celltrion's treatment options for autoimmune diseases. With approvals in over 50 countries, including Europe and Canada, Zymfentra's availability in the US market solidifies Celltrion's global presence.
According to KED Global, Celltrion credits the FDA's guidance and collaboration from the early negotiation stages for the smooth licensing process. Following the FDA's suggestions, Celltrion conducted two global Phase 3 clinical trials and submitted the approval application in December of last year.
"The approval of Zymfentra provides an innovative and effective treatment option that offers patients with inflammatory bowel disease an alternative administration option providing control of how and where they receive their treatment," said Thomas Nusbickel, chief commercial officer at Celltrion USA.
Projected Success, Revenue Forecast
With the expected launch of Zymfentra, Celltrion anticipates an annual turnover of over 600 billion won ($443.7 million) and a three-year revenue forecast of 3 trillion won. This exponential growth is attributed to collaborative synergies with Celltrion's existing US market entries, Remsima and Yuflyma, further consolidating their foothold in the US market.
To enhance cost efficiency, Celltrion plans to discontinue intermediary purchasing and selling activities through Celltrion Healthcare. The company aims to strengthen its direct sales network, allowing seamless access to Remsima SC in the US market.
Photo: Celltrion Newsroom
